

NATIONAL COLLABORATING CENTRE FOR CANCER (NCC-C)

Pancreatic Cancer

First Guideline Development Group (GC) meeting

3rd & 4th March 2016

Board Room, NCC-C, Park House, Greyfriars Road, Cardiff

GROUP MEMBERSHIP & ACTION LIST

GC Members	
Professor John Primrose (JP)	Lesley Goodburn (LG)
Professor John Neoptolemos (JN)	Anna Jewell (AJ)
Mark Callaway (MCal) (<i>Day 1 only</i>)	Laura McGeeney (LM)
Professor Fiona Campbell (FC)	Dr Somnath Mukherjee (SM)
Dr Margred Capel (MCap)	Dr Kofi Oppong (KO)
Mr Richard Charnley (RC)	Mr Derek O'Reilly (DOR)
Dr Pippa Corrie (PC)	Philip Whelan (PW)
Dawn Elliot (DE)	
NCC-C staff	
John Graham (JG)	Ferruccio Pelone (FP)
Angela Bennett (AB)	Elise Hasler (EH)
Dr Nathan Bromham (NB) (<i>Day 1 only</i>)	James Hawkins (JH)
Susan O'Connell (SOC)	
NICE staff	
Katie Perryman Ford (KPF)	Juliet Kenny (<i>Day 1 only</i>)
Apologies	
Suzanne Joharchi (SJ)	

REPORTS OF DISCUSSIONS AT THE MEETING

1. Introductions

JP welcomed everyone to the 1st meeting of the Pancreatic Cancer GC.

2. Declarations of Interest

The following declarations of interest were declared prior to the meeting:

Confirmed web minutes

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Professor John Primrose	Professor of Surgery, University of Southampton	Chief investigator and involved in designing the trial protocol for FACS (randomised controlled trial to assess the cost-effectiveness of intensive versus no scheduled follow-up in patients who have undergone resection for colorectal cancer with curative intent). Funded by NIHR HTA [declared on application 23.7.15]	Non-personal financial non-specific	No action needed
Professor John Primrose	Professor of Surgery, University of Southampton	Chief investigator and involved in designing the trial protocol for ORANGE-2 (Open Versus Laparoscopic Hemihepatectomy). Funded by Maastricht University Medical Center [declared on application 23.7.15]	Non-personal financial non-specific	No action needed
Professor John Primrose	Professor of Surgery, University of Southampton	Chief investigator and involved in designing the trial protocol for BILCAP (A randomised clinical trial evaluating adjuvant chemotherapy with capecitabine compared to expectant treatment alone following surgery for biliary tract cancer). Funded by CRUK [declared on application 23.7.15]	Non-personal financial non-specific	No action needed
Professor John Primrose	Professor of Surgery, University of Southampton	Chief investigator and involved in designing the trial protocol for EPOC B (An exploratory study to investigate the optimal scheduling of chemotherapy in patients with operable colorectal liver metastases). Funded by CTAAC [declared on application 23.7.15]	Non-personal financial non-specific	No action needed
Professor John Primrose	Professor of Surgery, University of Southampton	Chief investigator and involved in designing the trial protocol for New EPOC (A prospective randomised open label trial of oxaliplatin / irinotecan plus fluorouracil versus oxaliplatin / irinotecan plus fluorouracil and cetuximab pre and post operatively in patients with resectable colorectal liver metastases requiring	Non-personal financial non-specific	No action needed

Confirmed web minutes

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
		chemotherapy). Funded by CRUK [declared on application 23.7.15]		
Professor John Primrose	Professor of Surgery, University of Southampton	Chief investigator and involved in designing the trial protocol for ACTICCA-1 (Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma. A randomized, multidisciplinary, multinational AIO/DGAV/DGVS phase III trial). Funded by CTAAC. [declared on application 23.7.15]	Non-personal financial non-specific	No action needed
Professor John Primrose	Professor of Surgery, University of Southampton	Chief investigator and involved in designing the trial protocol for Trans EPOC (tissue collection for the EPOC study). Funded by CTAAC. [declared on application 23.7.15]	Non-personal financial non-specific	No action needed
Professor John Primrose	Professor of Surgery, University of Southampton	Chief investigator and involved in designing the trial protocol for Trans BILCAP (tissue collection for the BILCAP study). Funded by CRUK [declared on application 23.7.15]	Non-personal financial non-specific	No action needed
Professor John Primrose	Professor of Surgery, University of Southampton	Co-investigator (not involved in designing the trial protocol) for the TACE-2 trial (a randomised placebo-controlled, double blinded, phase III trial evaluating sorafenib in combination with transarterial chemoembolisation (TACE) in patients with unresectable hepatocellular carcinoma (HCC)). Funded by Bayer Ltd. [declared on application 23.7.15]	Non-personal financial non-specific	No action needed
Professor John Primrose	Professor of Surgery, University of Southampton	Department receives an infrastructure grant from CRUK which employs a clinical lecturer in general surgery. [declared on application 23.7.15]	Non-personal financial non-specific	No action needed

Confirmed web minutes

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Professor John Neoptolemos	The Owen and Ellen Evans Chair of Surgery, University of Liverpool and The Royal Liverpool & Broadgreen University Hospital NHS Trust	Received payment in September 2015 from Merck Serono Global for attending an advisory board for Pancreatic Cancer [declared on application 20.7.15]	Personal financial	
Professor John Neoptolemos	The Owen and Ellen Evans Chair of Surgery, University of Liverpool and The Royal Liverpool & Broadgreen University Hospital NHS Trust	Received payment in September 2014 from Amgen for giving a lecture on the role of adjuvant therapies for pancreatic cancer at a GI forum in Oslo, Norway [declared on application 20.7.15]	Personal financial specific/non-specific	No action needed as interest lapsed in September 2015
Professor John Neoptolemos	The Owen and Ellen Evans Chair of Surgery, University of Liverpool and The Royal Liverpool & Broadgreen University Hospital NHS Trust	Received payment in March 2014 from Abbott for giving a lecture on surgery criteria for resectability and results in pancreatic cancer at the Gastroenterology and Endoscopy service, Santa Maria Hospital, Lisbon. [declared on application 20.7.15]	Personal financial specific/non-specific	No action needed as interest lapsed in March 2015
Professor John Neoptolemos	The Owen and Ellen Evans Chair of Surgery, University of Liverpool and The Royal Liverpool & Broadgreen University Hospital NHS Trust	Received payment from KAEL-GemVax between September 2013 and August 2014 for the development of GV1001 (prognostic/predictive marker of survival in pancreatic cancer). [declared on application 20.7.15]	Personal financial specific/non-specific	No action needed as interest lapsed in August 2015
Professor John Neoptolemos	The Owen and Ellen Evans Chair of Surgery, University of Liverpool and The Royal Liverpool & Broadgreen University Hospital NHS Trust	Received an educational travel grant from NUCANA to attend the ASCO meeting in Chicago in 2015. [declared on application 20.7.15]	Personal financial non-specific	No action needed
Professor John Neoptolemos	The Owen and Ellen Evans Chair of Surgery, University of Liverpool and The Royal Liverpool & Broadgreen University Hospital NHS Trust	NIHR Senior Investigator from April 2011 to 2016 [declared on application 20.7.15]	Personal financial non-specific	No action needed

Confirmed web minutes

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Professor John Neoptolemos	The Owen and Ellen Evans Chair of Surgery, University of Liverpool and The Royal Liverpool & Broadgreen University Hospital NHS Trust	Has financial responsibility for an account which is used for pancreatic cancer research. No contributions to the fund from industry. [declared on application 20.7.15]	Non-personal financial non-specific	No action needed
Professor John Neoptolemos	The Owen and Ellen Evans Chair of Surgery, University of Liverpool and The Royal Liverpool & Broadgreen University Hospital NHS Trust	<p>Director of the Cancer Research UK Liverpool Cancer Trials Unit, which encompasses the CRUK trials unit (funded by CRUK), North West Surgical Trials Centre (funded by CRUK and Royal College of Surgeons of England) and the NIHR Clinical Trial Unit (Funded by NIHR). Within this unit:</p> <p>CRUK – funds a Senior Research Nurse.</p> <p>There is a laboratory services agreement with Merck. This agreement has been discharged and the surplus money is being used to support research within the department.</p> <p>Expects to sign a research agreement shortly to provide Taiho with immunohistochemistry staining of samples for the JASPAC-01 trial (Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer).</p> <p>Several trials being undertaken by the trials unit are supported by industry and this support includes funding/part funding of posts within the trials unit. [declared on application 20.7.15]</p>	Non-personal financial specific	No action needed as decisions on how funding is allocated and spent are made collectively.
Professor John Neoptolemos	The Owen and Ellen Evans Chair of Surgery, University of Liverpool and The Royal Liverpool & Broadgreen	Member of the independent trial steering committee (advise on safety, no involvement in designing trial protocol) for a randomized controlled trial of Hemopatch to prevent	Non-personal financial specific/non-specific	No action needed as no supervisory responsibility for the trial

Confirmed web minutes

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
	University Hospital NHS Trust	post-operative pancreatic duct fistula on the pancreatic stump after distal pancreatectomy. Funded by Baxter. [declared on application 20.7.15]		
Professor John Neoptolemos	The Owen and Ellen Evans Chair of Surgery, University of Liverpool and The Royal Liverpool & Broadgreen University Hospital NHS Trust	Co-principle investigator (designed trial protocol) for a prospective, phase II, double-blinded, multicentre, randomised clinical trial comparing combination gemcitabine and vandetanib therapy with gemcitabine therapy alone in advanced pancreatic cancer. Funded by Astra Zeneca. Trial has now closed but data analysis and reporting of results is ongoing. [declared on application 20.7.15]	Non-personal financial specific/non-specific	Leave the room for discussion of any topics which include vandetanib as an intervention
Professor John Neoptolemos	The Owen and Ellen Evans Chair of Surgery, University of Liverpool and The Royal Liverpool & Broadgreen University Hospital NHS Trust	National co-investigator (designed trial protocol) on ACELARATE trial (Phase III, open label, multicentre randomized clinical trial comparing Acelarin with Gemcitabine in patients with metastatic pancreatic adenocarcinoma). Funded by NUCANA. [declared on application 20.7.15]	Non-personal financial specific/non-specific	Leave the room for discussion of any topics which include acelararin as an intervention
Professor John Neoptolemos	The Owen and Ellen Evans Chair of Surgery, University of Liverpool and The Royal Liverpool & Broadgreen University Hospital NHS Trust	Co-investigator (provides scientific input and interpretation of data) for study on the role of monocytes in the metastatic process: identification of novel molecular targets to fight pancreatic cancer. Funded by Pancreatic Cancer Research Fund. [declared on application 20.7.15]	Non-personal financial specific/non-specific	No action needed as not involved in designing trial protocol and trial not funded by industry
Professor John Neoptolemos	The Owen and Ellen Evans Chair of Surgery, University of Liverpool and The Royal Liverpool & Broadgreen University Hospital NHS Trust	Principle investigator (responsible for doing the research and deciding how funds should be spent) on a study on the role of Eotaxin-1/CCR3 in human pancreatic cancer and as a prognostic and/or predictive marker of survival by GV1001. Funded by KAEL-GemVax. [declared on application 20.7.15]	Non-personal financial specific/non-specific	Leave the room for discussion of any topics which include Eotaxin-1/CCR3 or GV1001 as interventions

Confirmed web minutes

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Professor John Neoptolemos	The Owen and Ellen Evans Chair of Surgery, University of Liverpool and The Royal Liverpool & Broadgreen University Hospital NHS Trust	Co-investigator (provides scientific input and interpretation of data) for a study on validation of serum biomarkers for pancreatic cancer detection. Funded by North West Cancer Research. [declared on application 20.7.15]	Non-personal financial specific/non-specific	No action needed as not involved in designing trial protocol and trial not funded by industry
Professor John Neoptolemos	The Owen and Ellen Evans Chair of Surgery, University of Liverpool and The Royal Liverpool & Broadgreen University Hospital NHS Trust	Co-principal investigator (collect tissues and data) for European Study Group for Pancreatic Cancer Trial 5F prospective sample collection - ESPAC-5FT. Funded by Cancer Research UK [declared on application 20.7.15]	Non-personal financial specific/non-specific	No action needed as not involved in designing trial protocol and trial not funded by industry
Professor John Neoptolemos	The Owen and Ellen Evans Chair of Surgery, University of Liverpool and The Royal Liverpool & Broadgreen University Hospital NHS Trust	Co-principal investigator for ESPAC-5F Four arm, prospective, multicentre, randomised Phase II trial of immediate surgery compared with neoadjuvant chemotherapies and neoadjuvant chemoradiotherapy. Funded by Cancer Research UK [declared on application 20.7.15]	Non-personal financial specific/non-specific	No action needed as not involved in designing trial protocol and trial not funded by industry
Professor John Neoptolemos	The Owen and Ellen Evans Chair of Surgery, University of Liverpool and The Royal Liverpool & Broadgreen University Hospital NHS Trust	Co-principal investigator for European Study Group for Pancreatic Cancer (ESPA)-Trial 4. Combination versus single agent adjuvant chemotherapy in resectable pancreatic cancer. Funded by Cancer Research UK [declared on application 20.7.15]	Non-personal financial specific/non-specific	No action needed as not involved in designing trial protocol and trial not funded by industry
Professor John Neoptolemos	The Owen and Ellen Evans Chair of Surgery, University of Liverpool and The Royal Liverpool & Broadgreen University Hospital NHS Trust	Co-principal investigator (collect tissues and data) ESPAC 4T: European Study Group for Pancreatic Cancer Trial 4 prospective sample collection. Funded by Cancer Research UK [declared on application 20.7.15]	Non-personal financial specific/non-specific	No action needed as not involved in designing trial protocol and trial not funded by industry
Professor John Neoptolemos	The Owen and Ellen Evans Chair of Surgery, University of	Co-principal investigator for PANasta trial (Cattell Warren versus Blumgart techniques of pancreatico-	Non-personal financial specific/non-	No action needed as not involved in designing trial

Confirmed web minutes

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
	Liverpool and The Royal Liverpool & Broadgreen University Hospital NHS Trust	jejunostomy following pancreatoduodenectomy - a double blinded multi-centred trial). Funded by Cancer Research UK. [declared on application 20.7.15]	specific	protocol and trial not funded by industry
Professor John Neoptolemos	The Owen and Ellen Evans Chair of Surgery, University of Liverpool and The Royal Liverpool & Broadgreen University Hospital NHS Trust	Co-principal investigator for study on stratification of adjuvant chemotherapeutic response to allow personalised choice of pyrimidine prodrug: based on levels of transporters and enzymes involved in initial metabolism. Funded by Cancer Research UK [declared on application 20.7.15]	Non-personal financial specific/non-specific	No action needed as not involved in designing trial protocol and trial not funded by industry
Professor John Neoptolemos	The Owen and Ellen Evans Chair of Surgery, University of Liverpool and The Royal Liverpool & Broadgreen University Hospital NHS Trust	Principle investigator (designed trial protocol) for study on antioxidants and magnesium for the treatment of pain in hereditary and idiopathic chronic pancreatitis. Funded by Pharma Nord. [declared on application 20.7.15]	Non-personal financial non-specific	No action needed as non-specific to guideline
Mark Callaway	Consultant Radiologist, Bristol Royal Infirmary	Visiting Professor, University of the West of England, appointed in Dec 2015 [declared on application 13.01.16]	Personal financial non-specific	No action needed
Mark Callaway	Consultant Radiologist, Bristol Royal Infirmary	Partner in Bristol Radiology LLP [declared on application 13.01.16]	Personal financial specific	No action needed as long as topics only look at standard radiology interventions used in the NHS (approved by NICE)
Mark Callaway	Consultant Radiologist, Bristol Royal Infirmary	Director of MCallaway Medical Imaging Ltd [declared on application 13.01.16]	Personal financial specific	No action needed as long as topics only look at standard radiology interventions used in the NHS (approved by NICE)
Mark	Consultant	Trustee of Cobalt Health,	Non-	No action

Confirmed web minutes

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Callaway	Radiologist, Bristol Royal Infirmary	appointed in Dec 2015 [declared on application 13.01.16]	financial personal non-specific	needed
Mark Callaway	Consultant Radiologist, Bristol Royal Infirmary	Trustee of the Royal College of Radiologists [declared on application 13.01.16]	Non-financial personal non-specific	No action needed
Professor Fiona Campbell	Consultant Gastrointestinal Pathologist, Royal Liverpool University Hospital	On the medical advisory board for Pancreatic Cancer UK. Reviews content of patient information resources [declared on application 23.2.16]	Non-financial specific	No action needed
Professor Fiona Campbell	Consultant Gastrointestinal Pathologist, Royal Liverpool University Hospital	Collaborator providing pathology input to the ESPAC-4 (EUROPEAN STUDY GROUP FOR PANCREATIC CANCER - TRIAL 4. Combination versus single agent chemotherapy in resectable pancreatic ductal and peri-ampullary cancers.). Funded by CRUK [declared on application 23.2.16]	Non-personal financial specific/non-specific	No action needed as no supervisory responsibility for the trial
Professor Fiona Campbell	Consultant Gastrointestinal Pathologist, Royal Liverpool University Hospital	Collaborator providing pathology input to the VIP (A prospective, phase II, double blinded, multicentre, randomised clinical trial comparing combination gemcitabine and vandetanib therapy with gemcitabine therapy alone in locally advanced or metastatic pancreatic carcinoma.) Funded by Astra Zeneca [declared on application 23.2.16]	Non-personal financial specific/non-specific	No action needed as no supervisory responsibility for the trial
Professor Fiona Campbell	Consultant Gastrointestinal Pathologist, Royal Liverpool University Hospital	Collaborator providing pathology input to the PET-PANC (The impact of combined modality positron emission tomography with computerised tomography scanning (PET/CT) in the diagnosis and management of pancreatic cancer.) Funded by NIHR Health Technology Assessment [declared on application 23.2.16]	Non-personal financial specific/non-specific	No action needed as no supervisory responsibility for the trial
Professor Fiona Campbell	Consultant Gastrointestinal Pathologist, Royal Liverpool University Hospital	Collaborator providing pathology input to the ESPAC-5F (European Study Group for Pancreatic	Non-personal financial specific/non-	No action needed as no supervisory responsibility

Confirmed web minutes

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
	University Hospital	Cancer Trial 5F Four arm, prospective, multicentre, randomised feasibility trial of immediate surgery compared with neoadjuvant chemotherapies and neoadjuvant chemoradiotherapy.) Funded by CRUK [declared on application 23.2.16]	specific	for the trial
Professor Fiona Campbell	Consultant Gastrointestinal Pathologist, Royal Liverpool University Hospital	Collaborator providing pathology input to the ENDCaP (Enhanced Neoplasia Detection and Cancer Prevention in Chronic Colitis: A Multicentre test accuracy study). Funded by NIHR Efficacy and Mechanism Evaluation [declared on application 23.2.16]	Non-personal financial specific/non-specific	No action needed as no supervisory responsibility for the trial
Professor Fiona Campbell	Consultant Gastrointestinal Pathologist, Royal Liverpool University Hospital	Collaborator providing pathology input to the PANaSta (Cattell Warren versus Blumgart techniques of pancreatico-jejunostomy following pancreato-duodenectomy - a double blinded multicentred trial). Funded by CRUK [declared on application 23.2.16]	Non-personal financial specific/non-specific	No action needed as no supervisory responsibility for the trial
Professor Fiona Campbell	Consultant Gastrointestinal Pathologist, Royal Liverpool University Hospital	Collaborator providing pathology input to the ACELARATE (A Phase III, open label, multicentre randomised clinical study comparing Acelarin (NUC1031) with Gemcitabine in patient with metastatic pancreatic carcinoma.) funded by NuCana BioMed Ltd [declared on application 23.2.16]	Non-personal financial specific/non-specific	No action needed as no supervisory responsibility for the trial
Professor Fiona Campbell	Consultant Gastrointestinal Pathologist, Royal Liverpool University Hospital	Collaborator providing pathology input to the FOxTROT (Fluoropyrimidine, Oxaliplatin & Targeted Receptor pre-Operative Therapy for colon cancer. A randomised trial assessing whether preoperative chemotherapy and/or an anti-EGFR monoclonal	Non-personal financial specific/non-specific	No action needed as no supervisory responsibility for the trial

Confirmed web minutes

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
		antibody improves outcome in high-risk operable colon cancer.). Funded by CRUK [declared on application 23.2.16]		
Professor Fiona Campbell	Consultant Gastrointestinal Pathologist, Royal Liverpool University Hospital	Committee member of the Pancreatic Society of GB and Ireland. [declared on application 23.2.16]	Non-financial specific	No action needed
Dr Margred Capel	Consultant in Palliative Medicine, George Thomas Hospice	Local principal investigator on the OPTCARE NEURO trial (Evaluation of the clinical and cost-effectiveness of Short-term Integrated Palliative Care Services (SIPC) to OPTimise CARE for people with advanced long-term Neurological conditions. Funded by NIHR Health Services and Delivery Research. Responsible for administering the trial protocol locally. No involvement in designing the trial protocol. [declared on application 4.2.16]	Non-personal financial non-specific	No action needed
Dr Margred Capel	Consultant in Palliative Medicine, George Thomas Hospice	Member of the Association of Palliative Medicine professional standards committee – for example write symptom control guidelines. [declared on application 4.2.16]	Non-financial non-specific	No action needed
Mr Richard Charnley	Consultant Hepatobiliary and Pancreatic Surgeon, Freeman Hospital, Newcastle upon Tyne	Submitted patients to the ESPAC trials (all funded by CRUK). Involved in the study design for ESPAC-5 [declared on application 6.1.16]	Non-financial non-specific	No action needed
Mr Richard Charnley	Consultant Hepatobiliary and Pancreatic Surgeon, Freeman Hospital, Newcastle upon Tyne	Responsible for a general pancreatic research fund (used to support research and students) and a fund used specifically for research into ascinar cell tumours. No industry contributions to either fund. [declared on application 6.1.16]	Non-personal financial specific	No action needed
Mr Richard Charnley	Consultant Hepatobiliary and Pancreatic Surgeon, Freeman	On the Medical Advisory Board for Pancreatic Cancer UK. Assists with general awareness raising and	Non-financial non-specific	No action needed

Confirmed web minutes

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
	Hospital, Newcastle upon Tyne	member of the panel who score grant applications. [declared on application 6.1.16]		
Mr Richard Charnley	Consultant Hepatobiliary and Pancreatic Surgeon, Freeman Hospital, Newcastle upon Tyne	Published a pamphlet on pancreatic cancer supplementation in 2010 which was sponsored by Abbott. Received a fee [declared on application 6.1.16]	Personal financial specific	No action as interest has lapsed
Dr Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology, Cambridge University Hospitals NHS Foundation Trust	Received an honorarium for attendance at an advisory board from Celgene on abraxane in pancreatic cancer in March 2015. [declared on application 7.12.15]	Personal financial specific	Leave the room for discussion of any topics which include abraxane as an intervention until March 2016
Dr Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology, Cambridge University Hospitals NHS Foundation Trust	Received an honorarium for attendance at an advisory board from Roche on Melanoma systemic therapies in June 2015 [declared on application 7.12.15]	Personal financial non-specific	No action needed
Dr Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology, Cambridge University Hospitals NHS Foundation Trust	Received an honorarium for attendance at an advisory board from Novartis on Melanoma systemic therapies in June 2015 [declared on application 7.12.15]	Personal financial non-specific	No action needed
Dr Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology, Cambridge University Hospitals NHS Foundation Trust	Received an honorarium for attendance at an advisory board from BMS on Melanoma systemic therapies in July 2015 [declared on application 7.12.15]	Personal financial non-specific	No action needed
Dr Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology, Cambridge University Hospitals NHS Foundation Trust	Received an honorarium for attendance at an advisory board from Baxalta on liposomal irinotecan for advanced pancreatic cancer in November 2015 [declared on application 7.12.15]	Personal financial specific	Leave the room for discussion of any topics which include liposomal irinotecan as an intervention until March 2016
Dr Pippa	Consultant and	Received an honorarium for	Personal	No action

Confirmed web minutes

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Corrie	Associate Lecturer in Medical Oncology, Cambridge University Hospitals NHS Foundation Trust	attendance at an advisory board from Roche on Melanoma systemic therapies in December 2015 [declared on application 7.12.15]	financial non-specific	needed
Dr Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology, Cambridge University Hospitals NHS Foundation Trust	Received an honorarium for attendance at an advisory board from Roche on Melanoma systemic therapies in January 2016 [declared on application 7.12.15]	Personal financial non-specific	No action needed
Dr Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology, Cambridge University Hospitals NHS Foundation Trust	Received payment from Roche for a presentation on Overview of melanoma therapies to Roche employees as part of melanoma awareness week in May 2015 [declared on application 7.12.15]	Personal financial non-specific	No action needed
Dr Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology, Cambridge University Hospitals NHS Foundation Trust	Received payment from Novartis for a presentation on Use of systemic therapies for melanoma as demonstrated by patient cases in June 2015 [declared on application 7.12.15]	Personal financial non-specific	No action needed
Dr Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology, Cambridge University Hospitals NHS Foundation Trust	Received payment from Celgene for a presentation on treatment of advanced pancreatic cancer in September 2015 [declared on application 7.12.15]	Personal financial specific	Leave the room for discussion of topics including interventions made by Celgene until September 2016
Dr Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology, Cambridge University Hospitals NHS Foundation Trust	Received reimbursement of travel, registration and accommodation expenses for 30 May-2 June 2015 ASCO conference, Chicago from BMS [declared on application 7.12.15]	Personal financial non-specific	No action needed
Dr Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology, Cambridge University Hospitals NHS	Received reimbursement of travel, registration and accommodation expenses for September 2015, ECCO conference from BMS [declared on application 7.12.15]	Personal financial non-specific	No action needed

Confirmed web minutes

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
	Foundation Trust			
Dr Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology, Cambridge University Hospitals NHS Foundation Trust	Received reimbursement of travel, registration and accommodation expenses for November 2015, Society of Melanoma Research from BMS [declared on application 7.12.15]	Personal financial non-specific	No action needed
Dr Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology, Cambridge University Hospitals NHS Foundation Trust	Chairs an ISDMC on behalf of Celgene for the Celgene-sponsored international multiple myeloma trial, MM007 trial (previously received a fee and reimbursement of travel expenses) [declared on application 7.12.15]	Personal financial non-specific	No action needed
Dr Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology, Cambridge University Hospitals NHS Foundation Trust	Previously received a fee and reimbursement of travel expenses for being a member of the MM026 multiple myeloma trial [declared on application 7.12.15]	Personal financial non-specific	No action needed
Dr Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology, Cambridge University Hospitals NHS Foundation Trust	Chief investigator for AVAST-M trial (randomised trial evaluating the VEGF inhibitor, bevacizumab (Avastin), as adjuvant therapy following resection of AJCC stage IIB (T4aN0M0), IIC (T4bN0M0) and III (TxN1-2M0) cutaneous melanoma). Designed the trial protocol. Funded by CRUK. [declared on application 7.12.15]	Non-personal financial non-specific	No action needed
Dr Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology, Cambridge University Hospitals NHS Foundation Trust	Chief investigator for SIEGE trial (Randomised phase II trial to investigate two different schedules of nab-paclitaxel (Abraxane) combined with gemcitabine as first line treatment for metastatic pancreatic ductal adenocarcinoma). Designed the trial protocol. Funded by Celgene. [declared on application 7.12.15]	Non-personal financial specific	Leave the room for discussion of topics that include abraxane as an intervention
Dr Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology, Cambridge	Co-applicant for SCALOP2 – (A multi-centre randomised study of induction chemotherapy followed by capecitabine	Non-personal financial specific	Leave the room for discussion of topics that include

Confirmed web minutes

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
	University Hospitals NHS Foundation Trust	(+/-nelfinavir) with high or standard dose radiotherapy for locally advanced non-metastatic pancreatic cancer). Involved in designing trial protocol. Funded by CRUK and Celgene. [declared on application 7.12.15]		nelfinavir as an intervention
Dr Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology, Cambridge University Hospitals NHS Foundation Trust	Principle investigator for ESPAC-4 (Combination versus single agent chemotherapy in resectable pancreatic ductal and peri-ampullary cancers). Responsible for delivering the trial protocol locally. Funded by CRUK. [declared on application 7.12.15]	Non-personal financial specific/non-specific	No action needed as no supervisory responsibility for the trial
Dr Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology, Cambridge University Hospitals NHS Foundation Trust	Principle investigator for APACT (Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer). Responsible for delivering the trial protocol locally. Funded by Celgene. [declared on application 7.12.15]	Non-personal financial specific/non-specific	No action needed as no supervisory responsibility for the trial
Dr Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology, Cambridge University Hospitals NHS Foundation Trust	Principle investigator for PACMEL (A randomised phase 2 study of paclitaxel with or without GSK1120212 or pazopanib in advanced wt BRAF melanoma). Responsible for delivering the trial protocol locally. Funded by GSK. [declared on application 7.12.15]	Non-personal financial non-specific	No action needed
Dr Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology, Cambridge University Hospitals NHS Foundation Trust	Principle investigator for IMCgp100/01 (Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma). Responsible for delivering the trial protocol locally. Funded by Immunocore Ltd. [declared on application 7.12.15]	Non-personal financial non-specific	No action needed
Dr Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology,	Principle investigator for EORTC 18081 (Adjuvant peginterferon alfa-2b for 2 years vs Observation in	Non-personal financial non-specific	No action needed

Confirmed web minutes

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
	Cambridge University Hospitals NHS Foundation Trust	patients with an ulcerated primary cutaneous melanoma with T(2-4) bN0M0: a randomized phase III trial of the EORTC Melanoma Group). Responsible for delivering the trial protocol locally. Funded by EORTC. [declared on application 7.12.15]		
Dr Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology, Cambridge University Hospitals NHS Foundation Trust	Principle investigator for COLUMBUS (Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma). Responsible for delivering the trial protocol locally. Funded by Novartis. [declared on application 7.12.15]	Non-personal financial non-specific	No action needed
Dr Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology, Cambridge University Hospitals NHS Foundation Trust	Principle investigator for Millenium (Study of MLN2480 in Patients With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Patients With Metastatic Melanoma). Responsible for delivering the trial protocol locally. Funded by Millenium Pharmaceuticals Inc. [declared on application 7.12.15]	Non-personal financial non-specific	No action needed
Dr Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology, Cambridge University Hospitals NHS Foundation Trust	Principle investigator for EORTC 1325 (Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma). Responsible for delivering the trial protocol locally. Funded by Merck [declared on application 7.12.15]	Non-personal financial non-specific	No action needed
Dr Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology, Cambridge University Hospitals NHS Foundation Trust	Principle investigator for Sel-PAC (A Randomised three arm Randomised three arm, open label, Phase II study of continuous Selumetinib versus continuous or interrupted Selumetinib in combination with weekly Paclitaxel in	Non-personal financial non-specific	No action needed

Confirmed web minutes

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
		metastatic Uveal Melanoma). Responsible for delivering the trial protocol locally. Funded by Astra Zeneca [declared on application 7.12.15]		
Dr Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology, Cambridge University Hospitals NHS Foundation Trust	Principle investigator for ACELARATE (Phase III, open label, multicentre randomised clinical study comparing Acelarin (NUC1031) with Gemcitabine in patient with metastatic pancreatic carcinoma.) Responsible for delivering the trial protocol locally. Funded by NuCana BioMed Ltd [declared on application 7.12.15]	Non-personal financial specific/non-specific	No action needed as no supervisory responsibility for the trial
Dr Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology, Cambridge University Hospitals NHS Foundation Trust	Principle investigator for ACTICCA1 (A randomized, multidisciplinary, multinational AIO/DGAV/DGVS phase III trial of adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma). Responsible for delivering the trial protocol locally. Funded by CTAAC [declared on application 7.12.15]	Non-personal financial non-specific	No action needed
Dr Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology, Cambridge University Hospitals NHS Foundation Trust	Will be principal investigator on the forthcoming PERM trials (melanoma) [declared on application 7.12.15]	Non-personal financial non-specific	No action needed
Dr Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology, Cambridge University Hospitals NHS Foundation Trust	Has financial sign off (up to £5K) on a fund for melanoma and a fund for pancreatic cancer. Funds are used for research. No contributions to either fund from industry. [declared on application 7.12.15]	Non-personal financial specific	No action needed
Dr Pippa Corrie	Consultant and Associate Lecturer	Scientific advisor to Pancreatic Cancer UK. No	Non-financial	No action needed

Confirmed web minutes

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
	in Medical Oncology, Cambridge University Hospitals NHS Foundation Trust	fees received. Provides advice on strategy and reviews/updates patient information [declared on application 7.12.15]	personal specific	
Dr Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology, Cambridge University Hospitals NHS Foundation Trust	Trustee for Melanoma Focus. No fees received. Oversees strategy and general function of the charity. [declared on application 7.12.15]	Non-financial personal non-specific	No action needed
Dr Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology, Cambridge University Hospitals NHS Foundation Trust	Provided an overview of systemic therapy for advanced pancreatic cancer to Celgene in 2013. This was recorded and put on their website and also used in promotional literature. [declared on application 7.12.15]	Non-financial personal specific	No action needed as interest has lapsed
Dr Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology, Cambridge University Hospitals NHS Foundation Trust	Second author on a pamphlet on Pancreatic cancer – nabpaclitaxel. Gives an overview of the disease and the use of the drug in clinical practice – based on a review of existing literature. No fee received. Put together by Celgene and made available to clinicians. [declared on application 7.12.15]	Non-financial personal specific	No action needed
Dawn Elliot	[insert job title, organisation]	External Examiner for Hull University – BA and MSC in Gastroenterology. Paid a fee of £300/year. Performs quality assurance of marks given by course tutors. [declared on application 24.2.16]	Personal financial non-specific	No action needed
Dawn Elliot	[insert job title, organisation]	Is a signatory on a small fund (max £700) used for buying items for patients and supporting nurse training. Fund is from patient donations only – no industry contribution [declared on application 24.2.16]	Non-personal financial non-specific	No action needed
Lesley	Lay member	I am employed as a Service	Personal	No action

Confirmed web minutes

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Goodburn		Partner for Insight and Involvement at NHS Midlands and Lancashire Commissioning Support Unit. Involves advising on patient experience and getting patients involved in health and decision making. No specific focus on pancreatic cancer. [declared on application 25.2.16]	financial non-specific	needed
Lesley Goodburn	Lay member	Participated in a patient/carer board for Pancreatic Cancer UK in December 2015. Received reimbursement of travel expenses [declared on application 25.2.16]	Non-financial personal specific	No action needed
Lesley Goodburn	Lay member	Given £150 by Pancreatic Cancer UK to run a support group for patients with pancreatic cancer. Decides what the money is used on – typically mobile phones, business cards, printing. [declared on application 25.2.16]	Non-personal financial specific	No action needed
Anna Jewell	Lay member	The Charity that I work for is Pancreatic Cancer UK and they have received a small amount funding in the last 12 months from several pharmaceutical companies. This funding was used to support holding training events and conferences that we provide for health professionals. The companies did not get input into the content of the training events/conferences. None of the money was used to fund staff salaries. The companies include Celgene, Baxalta, Vitaflo and Mylan. [declared on application 25.2.16]	Non-personal financial specific	No action needed as companies only provide financial support for education events – no input into content
Anna Jewell	Lay member	Member of the Public Health England expert advisory group on cancer symptoms [declared on application 25.2.16]	Non-financial personal non-specific	No action needed
Anna Jewell	Lay member	Member of the NCIN clinical reference group for hepatobiliary cancers [declared on application	Non-financial personal non-specific	No action needed

Confirmed web minutes

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
		25.2.16]		
Anna Jewell	Lay member	Has been named on a variety of press releases on behalf of employer – Pancreatic Cancer UK	Non-financial personal specific	No action needed
Anna Jewell	Lay member	Named on a press release about NICEs technology appraisal decision on nabpaclitaxel	Non-financial personal specific	Leave the room for discussion of topics which include abraxane as an intervention
Suzanne Joharchi	Lay member	None		
Laura McGeeney	Specialist Pancreatic Dietician	My conference registration fees, hotel and travel expenses for the Pancreatic Society of Great Britain and Ireland in November 2015 were paid by the Nutrition Interest Group of the Pancreatic Society of Great Britain and Ireland (NIGPS) with money from a grant they received from Mylan. [declared on application 8.2.16]	Non-personal financial specific	No action needed
Laura McGeeney	Specialist Pancreatic Dietician	We have reps from companies that make nutritional supplements and enteral feeds come to our monthly departmental meetings, they sometimes bring lunch (sandwiches etc), I attend these meetings and eat the lunch they bring. [declared on application 8.2.16]	Non-financial personal non-specific	No action needed
Laura McGeeney	Specialist Pancreatic Dietician	Via an educational grant to NIGPS Mylan have funded food and delegate packs for education sessions I have taught on. [declared on application 8.2.16]	Non-financial personal non-specific	No action needed
Laura McGeeney	Specialist Pancreatic Dietician	I have recently joined the Medical Advisory Board of Pancreatic Cancer UK but have not yet undertaken any activity as part of this. [declared on application 8.2.16]	Non-financial personal specific	No action needed
Laura McGeeney	Specialist Pancreatic Dietician	I am the secretary of the Nutrition Interest Group of the Pancreatic Society of Great Britain and Ireland	Non-financial personal specific	No action needed

Confirmed web minutes

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
		(NIGPS) [declared on application 8.2.16]		
Dr Somnath Mukherjee	Senior Clinical Researcher & Consultant Clinical Oncologist, CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford & Churchill Hospital	Chief Investigator of the SCALOP-2 trial (A multi-centre randomised study of induction chemotherapy followed by capecitabine (+/-nelfinavir) with high or standard dose radiotherapy for locally advanced non-metastatic pancreatic cancer). Funded by Celgene and CRUK. Involved in designing the trial protocol. [declared on application 4.2.16]	Non-personal financial specific/non-specific	Leave the room for discussion of topics that include nelfinavir as an intervention
Dr Somnath Mukherjee	Senior Clinical Researcher & Consultant Clinical Oncologist, CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford & Churchill Hospital	Co-applicant on the NEO-Scope trial (A randomised Phase II study of two preoperative chemoradiotherapy regimes (oxaliplatin and capecitabine followed by radiotherapy with either oxaliplatin and capecitabine or paclitaxel and carboplatin) for resectable oesophageal cancer.). Funded by CRUK. Involved in designing the trial protocol. [declared on application 4.2.16]	Non-personal financial non-specific	No action needed
Dr Somnath Mukherjee	Senior Clinical Researcher & Consultant Clinical Oncologist, CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford & Churchill Hospital	Co-applicant on the CHARIOt trial (A Phase I trial of ATR inhibitor VX970 and radiotherapy in oesophageal cancer). Trial currently in set-up. [declared on application 4.2.16]	Non-personal financial non-specific	No action needed
Dr Somnath Mukherjee	Senior Clinical Researcher & Consultant Clinical Oncologist, CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford & Churchill Hospital	Member of the ASCO writing committee for their guideline on advanced pancreatic cancer. [declared on application 4.2.16]	Non-financial personal specific	No action needed
Dr Somnath Mukherjee	Senior Clinical Researcher & Consultant Clinical	Invited speaker at various events in 2015, on behalf of Celgene, to report on the	Personal financial non-specific	No action needed as just reimbursement

Confirmed web minutes

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
	Oncologist, CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford & Churchill Hospital	SCALOP-2 trial. No fee received – just reimbursement of travel expenses. No promotion of any particular intervention. [declared on application 4.2.16]		of travel expenses, no fee received
Dr Somnath Mukherjee	Senior Clinical Researcher & Consultant Clinical Oncologist, CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford & Churchill Hospital	Member of the NCRI upper GI clinical studies group and the pancreatic subgroup. [declared on application 4.2.16]	Non-financial personal specific	No action needed
Dr Somnath Mukherjee	Senior Clinical Researcher & Consultant Clinical Oncologist, CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford & Churchill Hospital	On the panel for the ESTRO European Radiotherapy guidelines for pancreatic cancer. [declared on application 4.2.16]	Non-financial personal specific	No action needed
Dr Kofi Oppong	Consultant Gastroenterologist, Newcastle upon Tyne University Hospitals NHS Trust	Flight and hotel 2 nights (approx. £600 total value) paid for by Medtronic/Covidien to present my experience of using their new EUS biopsy needle at their internal meeting and to enable me to attend part of the concurrent European gastroenterology meeting in Barcelona October 2015. Honorarium to be paid to research fund (no personal payment received). [declared on application 6.1.16]	Non-personal financial specific	No action needed
Dr Kofi Oppong	Consultant Gastroenterologist, Newcastle upon Tyne University Hospitals NHS Trust	£250 honorarium (to be paid to research fund) from Medtronic/Covidien for presenting a talk on EUS guided pancreatic biopsy at a session sponsored by the company at the European EUS meeting Glasgow November 2015. [declared	Non-personal financial specific	No action needed

Confirmed web minutes

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
		on application 6.1.16]		
Dr Kofi Oppong	Consultant Gastroenterologist, Newcastle upon Tyne University Hospitals NHS Trust	Submitted an application to Covidien for an investigator led study comparing biopsy yield in pancreatic masses with standard FNA needles compared with new core biopsy needles (both manufactured by Covidien). If application is granted, will be chief investigator and responsible for designing trial protocol. [declared on application 6.1.16]	Non-personal financial specific/non-specific	If application is successful will need to leave the room for any topics which are comparing FNA needles with core biopsy needles.
Dr Kofi Oppong	Consultant Gastroenterologist, Newcastle upon Tyne University Hospitals NHS Trust	Local PI for the CONCYST trial looking at needle confocal laser endomicroscopy in people with indeterminate pancreatic cysts [declared on application 6.1.16]	Non-personal financial non-specific	No action needed
Dr Kofi Oppong	Consultant Gastroenterologist, Newcastle upon Tyne University Hospitals NHS Trust	Chief investigator of study measuring pressure in the portal vein in patients with liver disease. Funded by University of Newcastle Biomedical Research Centre. [declared on application 6.1.16]	Non-personal financial non-specific	No action needed
Dr Kofi Oppong	Consultant Gastroenterologist, Newcastle upon Tyne University Hospitals NHS Trust	Is a co-signatory on a research fund held by the hospital Trust. Fund is used to cover expenses for CPD of department members and could be used in future to assist with research into hepatobiliary disease. No direct contributions to fund from industry – only indirect (i.e. any honorariums are paid to research fund rather than received personally). [declared on application 6.1.16]	Non-personal financial non-specific	No action needed
Dr Kofi Oppong	Consultant Gastroenterologist, Newcastle upon Tyne University Hospitals NHS Trust	On the British Society of Gastroenterology endoscopy committee, with a special responsibility for ERCP and EUS. No fees received. [declared on application 6.1.16]	Non-financial non-specific	No action needed
Dr Kofi Oppong	Consultant Gastroenterologist, Newcastle upon Tyne University Hospitals NHS	Next year will be president of the Pancreatic Society of GB and Ireland. Main responsibility will be to organise their annual	Non-financial non-specific	No action needed

Confirmed web minutes

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
	Trust	meeting. [declared on application 6.1.16]		
Mr Derek O'Reilly	Consultant Hepatobiliary and Pancreatic Surgeon, Manchester Royal Infirmary, Central Manchester NHS Foundation Trust	Celgene: Attendance at Platform for Exchange of Expertise and Research (PEER) in oncology meeting, London, 16-17 October 2005. Payment of: travel, accommodation, dinner and congress fee. [declared on application 5.1.16]	Personal financial non-specific	No action needed
Mr Derek O'Reilly	Consultant Hepatobiliary and Pancreatic Surgeon, Manchester Royal Infirmary, Central Manchester NHS Foundation Trust	Angiodynamics: Attendance at "The NanoKnife Training Lab" at Academic Medical Center (Irreversible Electroporation Training Course). Payment of: travel, accommodation, dinner and congress fee. [declared on application 5.1.16]	Personal financial specific/non-specific	No action needed
Philip Whelan	Macmillan Clinical Nurse Specialist, Royal Liverpool University Hospital	Attended an advisory board for Abbott in March 2015 about the use of Creon. Fee was donated to a support group for pancreatic cancer patients in Liverpool [declared on application 22.2.16]	Non-personal financial specific	No action needed
Philip Whelan	Macmillan Clinical Nurse Specialist, Royal Liverpool University Hospital	Reviews content of patient information resources for Pancreatic Cancer UK and Macmillan [declared on application 22.2.16]	Non-financial personal specific	No action needed
Philip Whelan	Macmillan Clinical Nurse Specialist, Royal Liverpool University Hospital	Has spoken, on behalf of Macmillan, at a variety of charity events to raise awareness of cancer in general. No fees received [declared on application 22.2.16]	Non-financial personal specific	No action needed

The GC were reminded that if they take on any new interests, these must be declared to the NCC-C as soon as they happen so that the necessary action can be taken.

3. Discussions

The GC were given presentations on:

- Introduction to NICE
- Introduction to NCC-C
- Timetable for guideline development and housekeeping
- Patient/Carer involvement in guideline development
- Guideline methodology development: From evidence to recommendations

Confirmed web minutes

- Guideline methodology development: Health Economics in NICE guidelines
- Technology appraisals and clinical guidelines.

The GC discussed the guideline scope and the topics that will be investigated. The group then drafted and agreed a PICO table for questions 3a, 3b, 5a, 5b, 5c, 5d, 5e, 5g, 5h and 5i. They also discussed the priority for economic investigation for each of these questions.

4. Close of meeting

JP thanked the GC for their input to the meeting, reminded them that the next meeting would be on **Monday 11th April 2016**, in Committee Room 1, RCOG, 27 Sussex Place, London and closed the meeting.